Clinical study
Enalapril reduces the albuminuria of patients with sickle cell disease

https://doi.org/10.1016/S0002-9343(99)80341-6Get rights and content

Purpose

To evaluate the effects of enalapril, an angiotensin-converting enzyme inhibitor, on albuminuria associated with sickle cell anemia.

Patients and methods

Two males and 6 females, mean age 22.8 ± 5.5 years, with sickle cell anemia and albuminuria, received enalapril for 6 months. Before entry into the study, all had a urinary albumin concentration above 30 mg/L as determined by radioimmunoassay documented on three separate occasions at intervals of 15 to 30 days. Samples were collected before 10 am after an oral water load of 10 mL/kg.

Results

Enalapril reduced 6 patients' pretreatment hyperalbuminuria to normal. One patient whose levels did not reach normal values experienced a reduction of 70%. Fractional excretion of sodium, potassium, and lithium did not change during the treatment. Mean arterial pressure decreased by 8.6 ± 0.42 mm Hg. Two years after enalapril was discontinued, there were no changes in sodium, potassium, or creatinine levels of 7 patients who had received enalapril or in their mean arterial pressures. Urinary albumin concentration increased relative to pretreatment levels in 2 individuals, returned to pretreatment levels in 2, and remained below 30 mg/L in 2.

Conclusion

Our results demonstrate that enalapril reduces albuminuria in patients with sickle cell anemia. After discontinuation of the drug, however, the albuminuria may increase to pretreatment levels or higher. Whether the reduction in urinary albumin concentration by angiotensin-converting enzyme inhibitors can delay the development of progressive renal failure in sickle cell anemia patients remains to be established.

References (36)

  • DeJong PE et al.

    The influence of indomethacin on renal hemodynamics in sickle cell anemia

    Clin Sci.

    (1980)
  • AllonM

    Renal abnormalities in sickle cell disease

    Arch Intern Med.

    (1990)
  • BakirM et al.

    Prognosis of the nephrotic syndrome in sickle glomerulopathy: a retrospective study

    Am J Nephrol.

    (1987)
  • MorganAG

    Proteinuria and leg ulcers in homozygous sickle cell disease J

    Trop Med Hyg.

    (1982)
  • MorganAG et al.

    Renal function in patients over 40 with homozygous sickle cell disease

    BMJ.

    (1981)
  • AndersonS et al.

    Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat

    J Clin Invest

    (1986)
  • MimranA et al.

    Comparative effect of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy

    Diabetes Care.

    (1988)
  • MarreM et al.

    Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria

    BMJ

    (1988)
  • Cited by (55)

    • Considerations for the future: current and future treatment paradigms with mineralocorticoid receptor antagonists—unmet needs and underserved patient cohorts

      2022, Kidney International Supplements
      Citation Excerpt :

      The pivotal role for RAS inhibitors in retarding the progression of kidney disease is well established.18 Surprisingly, in light of the predominance of hyperfiltration, very few reports have been made of studies of patients with SCD-related nephropathy who were treated with RAS inhibitors.19,20 A 2015 Cochrane database review reported the potential for reduction in albuminuria and proteinuria with the use of captopril in patients with SCD, compared with those without the disease.21

    • Progression of albuminuria in patients with sickle cell anemia: A multicenter, longitudinal study

      2020, Blood Advances
      Citation Excerpt :

      Our study provides new insight into the natural progression of albuminuria in SCA that is needed for the successful design of such studies. Our longitudinal study confirms previously reported findings and associations of sickle nephropathy.8,44,48-53 First, high baseline prevalence of albuminuria in a third of SCA patients was observed in our study.49-51,54

    • A Growing Population of Older Adults with Sickle Cell Disease

      2019, Clinics in Geriatric Medicine
      Citation Excerpt :

      Acceleration of renal impairment should prompt investigation of common comorbidities, in particular, hypertension and diabetes.17 Observational data have shown that proteinuria responds to treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and treatment with these agents should be considered when the urine protein/creatinine ratio is persistently elevated greater than 50 mg/mmol.49,50 Disease-modifying therapy (HU) should be considered alongside this specific treatment.48,51

    • American Society of Hematology 2019 guidelines for sickle cell disease: Cardiopulmonary and kidney disease

      2019, Blood Advances
      Citation Excerpt :

      Urine albumin was reported in 1 RCT (n = 22)85 and 7 observational studies (total n = 114).86-92 In the 6 studies that examined ACEi therapy, 53 of 84 patients (63%) who received ACEi therapy showed improvement in urine albumin.86-88,90-92 Of those who improved while receiving ACEi therapy, 18 (34%) had severe albuminuria (macroalbuminuria), 6 (11%) had moderate albuminuria (microalbuminuria), and the rest did not have their degree of albuminuria specified.

    • How I treat the older adult with sickle cell disease

      2018, Blood
      Citation Excerpt :

      Relevant to patient 1, observational data have shown that proteinuria responds to treatment with ACE inhibitors or angiotensin receptor blockers. Although there are no published guidelines on when to introduce ACE inhibitors or angiotensin receptor blockers, all adults should have urinary protein measurements performed at least annually and treatment with these agents should be considered when uPCR is persistently >50 mg/mmol.30,31 Disease-modifying therapy (HU) should be considered alongside this specific treatment.21,32

    View all citing articles on Scopus
    View full text